In a surprising turn of events, indie game Schedule I, a dope pushing simulator, has been accused of copyright infringement by Movie Games S.A., the developers behind The Drug Dealer Simulator series. According to a report from the Polish Press Agency on April 3, Movie Games S.A. alleges that Schedule I may have infringed upon their intellectual property rights by copying elements such as plot, mechanics, and even the user interface of The Drug Dealer Simulator games. Despite no official outcome from the investigation yet, the gaming community has already taken sides, with a significant show of support for Schedule I.
In response to the accusation, fans have rallied behind Schedule I, leading to a wave of negative reviews for Movie Games S.A.'s titles, The Drug Dealer Simulator and Drug Dealer Simulator 2, on Steam. These games are now rated as "Overwhelmingly Negative" and "Mostly Negative" respectively. The backlash largely stems from accusations of bullying against the indie developer and perceived hypocrisy, as Movie Games S.A. had not previously challenged similar titles until Schedule I's release. This reaction is noteworthy, given that The Drug Dealer Simulator series has been praised as one of the top criminal management games by various media and fans.
Schedule I Recent Updates
Schedule I’s Copyright Infringement Accuser Gets Review Bombed on Steam
Schedule I, a new cooperative crime simulation game, allows players to begin as a small-time dope pusher and rise to become a kingpin. Launched into Early Access on PC on March 25, it has garnered "Overwhelmingly Positive" reviews on Steam and is currently ranked as the platform's 2nd top-selling game, surpassing titles like inZOI, Monster Hunter Wilds, and the indie game R.E.P.O. SteamDB reports that Schedule I has reached an all-time peak of 459,075 concurrent players.
At Game8, we found Schedule I to be a surprisingly addictive and rewarding experience, likening it to a "Breaking Bad" simulator. For a deeper dive into our impressions of Schedule I's early access release, feel free to explore our detailed article below!
